Politics
President Donald Trump signed an executive order aimed at accelerating clinical research and federal approval for psychedelic therapies especially ibogaine as mental health therapy for veterans.
While state legislatures across the U.S. are creating task forces to evaluate proposed legislation to regulate psychedelic-assisted therapies, there remains a disconnect between what advocates want and what legislators are willing to pass without a clear ask, incremental steps, and effective bill language.
The Veterans Health Administration Novel Therapeutics Preparedness Act is the fourth psychedelics-related bill filed in Congress this term as related legislation gains momentum.
The rescheduling of cannabis by executive order and the FDA’s acceleration of research into potential 5-MeO-DMT therapies reflects expanded federal support for clinical investigations into psychedelic-assisted treatments in the U.S.
Lawmakers in Washington state have been debating two distinct and often conflicting visions for the regulation of psychedelics that reflects national tensions about the future of psychedelic therapies.
The passage of New Jersey Assembly Bill 3852, which creates a psilocybin therapy pilot program, exposed deep rifts between advocates seeking a medicalized pharmaceutical-led model and those supporting a community-based framework to regulate less costly psilocybin mushrooms.
The arrest of Jeremy O. Harris at a Japanese airport for allegedly possessing a small quantity of MDMA in his luggage highlights the country’s stringent drug laws and ongoing uncertainty about whether the playwright will still be indicted on drug charges after his release.
After decades shaping end-of-life law, attorney Kathryn Tucker is taking on federal bureaucracy to make psilocybin a legal medicine for those with no time to wait.
A proposed bill now being considered by the New York State Assembly would reform criminal penalties against psilocybin under state law and create a regulated public-health framework for dispensing psilocybin to adults by licensed providers for medical use.
As new psychedelic reform bills and ballot initiatives sweep the nation, the failure of the Question 4 ballot initiative in Massachusetts last year offers an instructive case study.
